Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8657832rdf:typepubmed:Citationlld:pubmed
pubmed-article:8657832lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:8657832lifeskim:mentionsumls-concept:C0026606lld:lifeskim
pubmed-article:8657832lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8657832lifeskim:mentionsumls-concept:C0814083lld:lifeskim
pubmed-article:8657832lifeskim:mentionsumls-concept:C1512045lld:lifeskim
pubmed-article:8657832lifeskim:mentionsumls-concept:C0049894lld:lifeskim
pubmed-article:8657832pubmed:issue4lld:pubmed
pubmed-article:8657832pubmed:dateCreated1996-7-30lld:pubmed
pubmed-article:8657832pubmed:abstractTextDose-dependent effects of 7-OH-DPAT on several behaviors, including place preference, were assessed. Three 2-day conditioning trials were conducted. On 1 day, animals received an injection of one of eight doses of 7-OH-DPAT (0-5 mg/kg) and were placed into a distinct compartment for 40 min. On the other day, animals received an injection of saline and were placed into a different compartment for 40 min. Locomotion, sniffing, and yawning were measured following the first and last injection of 7-OH-DPAT. Place conditioning was assessed on the day following the last trial. 7-OH-DPAT produced a U-shaped dose-dependent change in locomotion and sniffing, and an inverted U-shaped dose-dependent change in yawning. Additionally, repeated administration of 0.1 mg/kg sensitized yawning, whereas 5 mg/kg sensitized locomotion. None of the doses of 7-OH-DPAT produced conditioned place preference, however, there was a trend for conditioned place aversion at 0.03 mg/kg. By contrast, LiCl (127 mg/kg) produced conditioned place aversion and amphetamine (1 mg/kg) produced conditioned place preference using the same conditioning parameters. A subsequent experiment in which the number of animals and conditioning trials were increased demonstrated that the 0.03 mg/kg dose of 7-OH-DPAT produced conditioned place aversion. 7-OH-DPAT has a higher affinity for D3 receptors relative to D2 receptors. Therefore, it is suggested that intermediate doses (0.01-0.1 mg/kg) that increase yawning, and decrease locomotion and sniffing, may preferentially occupy D3 receptors. Furthermore, the results suggest that these putative D3-preferring doses have weak aversive effects.lld:pubmed
pubmed-article:8657832pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:languageenglld:pubmed
pubmed-article:8657832pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:citationSubsetIMlld:pubmed
pubmed-article:8657832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8657832pubmed:statusMEDLINElld:pubmed
pubmed-article:8657832pubmed:monthDeclld:pubmed
pubmed-article:8657832pubmed:issn0033-3158lld:pubmed
pubmed-article:8657832pubmed:authorpubmed-author:BakerD ADAlld:pubmed
pubmed-article:8657832pubmed:authorpubmed-author:NeisewanderJ...lld:pubmed
pubmed-article:8657832pubmed:authorpubmed-author:KhroyanT VTVlld:pubmed
pubmed-article:8657832pubmed:issnTypePrintlld:pubmed
pubmed-article:8657832pubmed:volume122lld:pubmed
pubmed-article:8657832pubmed:ownerNLMlld:pubmed
pubmed-article:8657832pubmed:authorsCompleteYlld:pubmed
pubmed-article:8657832pubmed:pagination351-7lld:pubmed
pubmed-article:8657832pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:meshHeadingpubmed-meshheading:8657832-...lld:pubmed
pubmed-article:8657832pubmed:year1995lld:pubmed
pubmed-article:8657832pubmed:articleTitleDose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning.lld:pubmed
pubmed-article:8657832pubmed:affiliationDepartment of Psychology, Arizona State University, Tempe 85287-1104, USA.lld:pubmed
pubmed-article:8657832pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8657832pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed